Medical Licensing (MD/DO) · Independent exam preparation
Pain Medicine One-Day Exam Study Guide
Practise pain classification, safer prescribing, procedural risk recognition, and syndrome-based decisions for ABFM's physician-level Pain Medicine CAQ exam.
By CertMedbry · Updated 19 October 2026
Practise distinguishing pain mechanisms, recognizing urgent syndromes, selecting treatments, and measuring meaningful functional benefit. This selective 60-concept guide follows the shared Pain Medicine examination blueprint's equal emphasis on General and Clinical States. The official ABA blueprint and detailed content outline define the full examination scope. Additional study remains necessary for detailed regional anatomy and procedural technique, neuroablation, regenerative interventions, pelvic and urologic syndromes, neonatal pain-system development, sex and gender effects, disability evaluation, and jurisdiction-specific regulation.
Try 20 free practice questionsWhat is the exam format?
Check the question types, timing and outline before planning your revision.
Which certification pathway does this guide address?
The selected pathway is initial ABFM Pain Medicine CAQ certification through the Pain Medicine One-Day Exam. ABFM requires ongoing family medicine certification, qualifying ACGME-accredited Pain Medicine fellowship training, an approved application, and a passing examination. This is a physician subspecialty credential in the United States certification system.
Why is an ABA blueprint applicable to an ABFM CAQ?
ABFM explicitly partners with ABA and directs candidates to ABA for examination content. The 2026 ABFM booklet states that participating boards share examination content and scoring, although application requirements differ. ABFM remains the awarding board for this pathway.
ABFM: Pain Medicine One-Day Exam · 2026 Pain Medicine CAQ One-Day Examination Information Booklet
How many questions are administered, and how many are scored?
The 2026 ABFM booklet specifies 200 questions in two sections of 100. It does not establish a separate scored-versus-pretest question count.
2026 Pain Medicine CAQ One-Day Examination Information Booklet
How long is the examination?
Each 100-question section allows up to two hours, giving four hours of testing. An optional break of up to 20 minutes follows the first section. The booklet describes an approximately five-hour appointment including the optional tutorial, instructions, testing, and breaks. Although officially named the One-Day Exam, it is described as a half-day computer-based examination.
2026 Pain Medicine CAQ One-Day Examination Information Booklet
What delivery method and item style are verified?
ABA administers the computer-based examination through Pearson VUE test centers. The booklet specifies single-best-answer multiple-choice questions and an absolute passing standard. The ABA blueprint describes three-response-option items and static-image questions. These 20 independent educational drills use four options. The booklet does not establish a numerical passing score.
ABFM: Pain Medicine One-Day Exam · 2026 Pain Medicine CAQ One-Day Examination Information Booklet · Pain Medicine Exam Blueprint
Which blueprint version and dates apply?
The examination booklet is labeled 2026 and v.1.0; its cover lists September 26, 2026 for initial certification. The Pain Medicine Exam Blueprint linked by ABA prints no revision or effective date, and its 2023 URL directory is not an effective date. The separate detailed Pain Medicine Examination Content Outline is labeled November 2024.
2026 Pain Medicine CAQ One-Day Examination Information Booklet · ABA: Pain Medicine Exam · Pain Medicine Exam Blueprint · PM_Content_Outline.pdf
How is examination content weighted?
General accounts for 50%: Background Concepts 5%, Assessment of Pain 5%, Pharmacotherapy 15%, Procedural Treatment 15%, and Psychological, Physical, and Integrative Therapies 10%. Clinical States accounts for 50%: Classification 1%, Chronic Widespread Pain 1%, Acute/Traumatic/Procedural Pain 6.5%, Musculoskeletal Pain 12.5%, Cancer Pain 6%, Visceral Pain 4%, Headache/Orofacial Pain 3%, Neuropathic Pain 8%, and Special Cases 8%. The guide allocates 30 concepts to each major domain; each practice set allocates 10 items to each.
How do maintenance and regaining certification differ?
Currently certified ABFM Pain Medicine physicians maintain the examination component through Longitudinal Assessment–Pain Medicine, or LA-PM. The one-day examination also provides a route for physicians whose Pain Medicine certification has lapsed to regain certification. This guide addresses initial certification.
ABFM: Pain Medicine · 2026 Pain Medicine CAQ One-Day Examination Information Booklet
This guide addresses the physician subspecialty Certificate of Added Qualification in Pain Medicine awarded by ABFM. Its questions and flashcards are independently authored educational materials, without official-item status or pass prediction.
Outline used: 2026 ABFM Pain Medicine Certificate of Added Qualification One-Day Examination Information Booklet, file designated v.1.0; Pain Medicine Exam Blueprint currently linked by ABA, with no printed revision or effective date. The assigned workbook label identifies the ABFM credential earned through this shared examination; the assigned slug is preserved.
60 key concepts: understand, apply and avoid the traps
Work through the questions by exam domain. Explain the answer in your own words, try the example, then check the common pitfall.
General50%
1.How does pain differ from nociception?
Pain is an unpleasant sensory and emotional experience associated with, or resembling that associated with, actual or potential tissue damage. Nociception is the neural encoding of noxious stimuli. They are related but distinct: nociceptive activity does not by itself establish a person's pain experience, and pain does not require visible tissue injury. Assessment therefore combines the patient's report with examination and context rather than using imaging as a pain detector.
Apply it
A patient reports persistent burning discomfort despite an unrevealing radiograph. Acknowledge the pain, examine sensory function, and investigate plausible mechanisms instead of concluding that a normal image disproves the reported experience or its functional consequences.
Common pitfall: Equating pain with visible damage can invalidate symptoms and miss neuropathic or nociplastic mechanisms. Conversely, acknowledging pain does not establish a particular diagnosis or treatment.
2.What distinguishes peripheral from central sensitization?
Peripheral sensitization increases responsiveness and reduces the threshold of nociceptive neurons in the periphery. Central sensitization increases responsiveness of nociceptive neurons in the central nervous system to normal or subthreshold afferent input. Both can amplify pain, but they identify different physiological locations. Clinical hypersensitivity may suggest altered processing; it does not independently prove which neurons are sensitized or replace investigation of an underlying lesion or inflammatory process.
Apply it
After a tissue injury, a patient develops tenderness near the wound and sensitivity beyond its margins. Consider peripheral and central contributions while assessing healing, neurological findings, and function rather than inferring one mechanism from pain intensity alone.
Common pitfall: Calling every severe or unexplained pain state central sensitization overstates what bedside findings establish. Sensitization is a physiological mechanism, not a synonym for psychological distress.
3.How is number needed to treat calculated?
For a beneficial binary outcome, calculate the absolute increase in response by subtracting the control response proportion from the treatment response proportion. Number needed to treat is its reciprocal, rounded upward to a whole person. Interpret it with the outcome definition, follow-up interval, uncertainty, and baseline risk. Relative effects alone cannot supply the absolute benefit, and an NNT from one population may not transfer unchanged to another.
Apply it
At twelve weeks, meaningful relief occurs in 60% of treated participants and 40% of controls. The absolute benefit is 0.20, so the NNT is five for one additional responder over that specific follow-up period.
Common pitfall: Dividing by the relative improvement produces the wrong NNT. A favorable benefit estimate also says nothing by itself about adverse effects or treatment burden.
Cochrane Handbook, Chapter 15: Interpreting results and drawing conclusions
4.How does PEG improve pain follow-up?
PEG assesses average pain intensity, interference with enjoyment of life, and interference with general activity. Repeated measurement helps distinguish symptom change from changes in daily participation. Pair the instrument with a concrete patient goal, such as walking to a nearby shop or completing a work shift. A lower intensity score without functional improvement warrants reassessment of benefit, adverse effects, and the broader treatment plan rather than automatic escalation.
Apply it
A patient's pain falls from eight to six, but sedation prevents preparing meals. Review PEG interference scores and the agreed cooking goal before calling treatment successful or increasing the medication to pursue a lower number.
Common pitfall: Using only the intensity item can conceal worsening function. PEG supports longitudinal assessment; it does not identify the anatomical pain generator or dictate a medication dose.
CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022
5.Which factors belong in a multidimensional pain assessment?
A useful assessment characterizes location, time course, quality, provoking factors, examination findings, and effects on function. It also evaluates sleep, mood, substance use, prior treatment responses, and the patient's goals. These dimensions influence both suffering and treatment safety. Depression or anxiety may coexist with structural disease, so their presence should broaden management rather than terminate diagnostic reasoning or invalidate the patient's account of pain.
Apply it
A warehouse worker with persistent back pain reports insomnia, low mood, and difficulty lifting. Assess neurological findings and work demands alongside emotional symptoms, then establish a functional goal that rehabilitation and symptom treatment can address together.
Common pitfall: Treating psychosocial assessment as a search for evidence against the patient misses its purpose. Mood, sleep, and social circumstances are clinically relevant treatment targets.
CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022
6.What evidence supports a neuropathic pain mechanism?
Neuropathic pain is caused by a lesion or disease of the somatosensory nervous system. Burning, electric shocks, or touch sensitivity can raise suspicion, but symptom words alone are insufficient. Look for an anatomically plausible distribution, relevant neurological disease or injury, and compatible sensory findings. This distinction matters because treatment selection and investigation depend on identifying the responsible disease rather than simply labeling all persistent pain as neuropathic.
Apply it
A patient describes burning feet with symmetrical distal sensory loss and established diabetes. The distribution, examination, and disease history support a neuropathic mechanism more strongly than the word burning would in an otherwise unexplained regional pain complaint.
Common pitfall: Allodynia can occur in several pain mechanisms. Its presence does not independently demonstrate a somatosensory lesion or prove that a gabapentinoid is appropriate.
IASP Terminology · AAN: Oral and Topical Treatment of Painful Diabetic Polyneuropathy
7.How should effective drug classes be compared for painful diabetic neuropathy?
The AAN supports TCAs, SNRIs, gabapentinoids, and sodium-channel blockers, and recommends against opioids, including tramadol and tapentadol. Compare representative agents: [duloxetine](https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a95cc04c-58e9-487f-8992-ef30df03a3cd) inhibits serotonin and norepinephrine reuptake; nausea and blood-pressure increases matter, and use should be avoided with chronic liver disease or GFR below 30 mL/min. MAOI combinations are contraindicated. [Amitriptyline](https://www.dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=23ab2afe-06c1-fa61-e063-6394a90abcf8) also inhibits monoamine reuptake but adds substantial anticholinergic effects, sedation, orthostasis, and conduction risk; urinary retention and angle-closure glaucoma are important cautions. [Pregabalin](https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b2b81bb6-5423-4221-8a61-f70a38d6a1e9) binds the alpha-2-delta calcium-channel subunit rather than GABA receptors; dizziness, somnolence, edema, renal dose adjustment, and respiratory risk with opioids matter. [Oxcarbazepine](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=188a48ad-c412-416a-b15b-de5f232740a2) is a sodium-channel blocker; hyponatremia, rash, dizziness, and adjustment for severe renal impairment distinguish it.
Apply it
A 58-year-old with painful diabetic neuropathy and depression has eGFR 75 mL/min/1.73 m², normal liver tests, controlled blood pressure, no MAOI or other interacting serotonergic treatment, and troublesome edema with pregabalin. Duloxetine is a reasonable different-class choice addressing both conditions. Monitor nausea, blood pressure, mood, pain interference, and function. If GFR were below 30 or chronic liver disease were present, this selection would change.
Common pitfall: Class efficacy does not make individual drugs interchangeable. Distinguish formal contraindications from cautions and organ-function restrictions; a nonopioid label does not remove sedation, interaction, or respiratory risk.
AAN: Oral and Topical Treatment of Painful Diabetic Polyneuropathy · AAN Issues Guideline for Treatment of Painful Diabetic Neuropathy · NCI: Cancer Pain (PDQ), Health Professional Version · FDA: Gabapentin and pregabalin — serious breathing problems
8.When should painful neuropathy treatment change classes?
The AAN describes treatment failure when a medication has been titrated to a demonstrated efficacious dose for approximately 12 weeks without clinically significant pain reduction, or earlier when adverse effects outweigh benefit. Confirm adherence, affordability, and the diagnosis before interpreting inadequate efficacy. Offer a different effective class after failure. For partial improvement, either switching to another effective class or adding a medication from a different effective class is an option, balancing additional benefit against interactions and adverse effects.
Apply it
After approximately 12 weeks at a demonstrated efficacious gabapentinoid dose without meaningful benefit, offer another effective class. Duloxetine can be reasonable with coexisting depression if renal function, liver status, blood pressure, and interactions permit. If there is useful but incomplete relief and acceptable tolerability, discuss adding a different class as an alternative to switching.
Common pitfall: A brief low-dose exposure does not establish efficacy failure. The approximately 12-week criterion does not require continuing a drug whose adverse effects already outweigh its benefit.
AAN: Oral and Topical Treatment of Painful Diabetic Polyneuropathy · NCI: Cancer Pain (PDQ), Health Professional Version
9.Why can gabapentinoid combinations threaten breathing?
Gabapentin and pregabalin can cause serious breathing problems, particularly with opioids or other central nervous system depressants, underlying respiratory impairment, and older age. Risk assessment must therefore consider the whole medication list and the patient's pulmonary status. New extreme sleepiness, slowed or difficult breathing, confusion, or inability to awaken requires urgent attention. A nonopioid designation does not mean a drug lacks sedation or interaction-related respiratory risk.
Apply it
An older patient with chronic obstructive pulmonary disease takes an opioid and develops marked sleepiness after pregabalin is added. Evaluate for respiratory depression promptly and reassess the combination rather than treating the change as an expected harmless adjustment.
Common pitfall: Monitoring pain relief alone can miss developing toxicity. Gabapentinoids are not respiratory-neutral alternatives when combined with opioids in a patient with additional risk factors.
10.How should an opioid trial begin when justified?
For adults within the CDC guideline's outpatient scope, consider an opioid when expected benefits for pain and function outweigh risks after discussing alternatives. Start with an immediate-release formulation at the lowest effective dosage, establish functional goals, and discuss an exit strategy. Reassess benefits and risks within 1–4 weeks after starting opioids for subacute or chronic pain or increasing the dosage, with earlier review when risk warrants it. This interval is a clinical recommendation rather than a legal deadline.
Apply it
If an opioid trial is justified for an opioid-naive adult with persistent noncancer pain, define an activity goal, select an immediate-release formulation, and schedule reassessment within 1–4 weeks. Arrange earlier review for increased respiratory or medication-interaction risk.
Common pitfall: Starting a long-acting formulation to simplify dosing can expose an opioid-naive patient to unnecessary risk. A trial should not become indefinite treatment through prescription renewal without reassessment.
CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022
11.How should continuing opioid benefit be judged?
Compare sustained pain and functional benefit with adverse effects and overdose risk, using agreed goals and repeated assessment. The CDC suggests reassessing ongoing long-term opioid therapy every three months or more frequently, with shorter intervals for higher-risk patients. Starting therapy for subacute or chronic pain or increasing dosage calls for reassessment within 1–4 weeks, sooner when warranted. These are clinical recommendations, not legal deadlines. Physical dependence alone establishes neither effectiveness nor opioid use disorder.
Apply it
A patient walks daily and works part-time without sedation despite persistent pain. Assess those gains and remaining risks at scheduled follow-up; review more frequently if depression, sedating combinations, or other overdose risks develop.
Common pitfall: A stable prescription is not proof of benefit, and persistent pain is not proof of failure. Do not let routine refills replace risk-based reassessment.
CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022
12.Why must long-term opioid tapering be individualized?
Patients receiving long-term opioids can develop physical dependence, making abrupt cessation or rapid reduction harmful. Unless a life-threatening issue requires immediate action, the CDC recommends collaborative, gradual changes when tapering is indicated. Duration of prior therapy, withdrawal symptoms, mental health, and patient goals influence the pace. Tapers may need pauses or adjustments, and nonopioid pain care should continue throughout rather than being postponed until opioid discontinuation.
Apply it
A patient taking opioids for years requests reduction but develops withdrawal and worsening distress during the initial plan. Slow or pause the taper, reassess support needs, and continue pain treatment instead of enforcing an inflexible calendar.
Common pitfall: A dosage threshold is not an instruction to abruptly discontinue therapy. Physical dependence also differs from opioid use disorder, which requires a separate diagnostic assessment.
CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022
13.When should naloxone accompany opioid care?
Offer naloxone when prescribing opioids, particularly when overdose risk is increased by prior overdose, substance use disorder, sleep-disordered breathing, higher opioid exposure, or concurrent benzodiazepines. Explain overdose recognition and response to patients and household members. Naloxone is an additional protective measure rather than a reason to accept an otherwise unsafe regimen. Risk assessment should also address sedating combinations, follow-up, and conditions that increase vulnerability to respiratory depression.
Apply it
A patient receiving an opioid also takes a benzodiazepine and has obstructive sleep apnea. Offer naloxone and household education while coordinating medication review and evaluating respiratory risk rather than treating naloxone as the only needed intervention.
Common pitfall: Restricting naloxone to people with diagnosed opioid use disorder misses patients at risk from prescribed combinations or medical comorbidity. Rescue access does not eliminate overdose risk.
CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022
14.How do patient risks shape NSAID selection?
NSAIDs can improve pain in appropriate musculoskeletal conditions, but oral treatment carries gastrointestinal, renal, and cardiovascular risks. Selection should consider kidney disease, prior bleeding, cardiovascular history, concurrent medicines, and treatment duration. A strong recommendation for efficacy in a condition does not mean universal suitability. Where supported for the affected joint, topical treatment can be considered before oral treatment to reduce systemic exposure while still monitoring tolerability and response.
Apply it
A patient with knee osteoarthritis and a history of gastrointestinal bleeding requests an oral NSAID. Review individual risks and discuss a supported topical option instead of interpreting an osteoarthritis guideline as an instruction to prescribe oral therapy universally.
Common pitfall: Topical administration reduces systemic exposure but does not make adverse effects impossible. Conversely, acetaminophen and NSAIDs are not interchangeable drugs with identical benefits and risks.
CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022 · 2026 Update of the American College of Rheumatology Recommendations for the Management of Osteoarthritis of the Knee, Hip, and Hand
15.How should monitoring information influence opioid decisions?
Prescription-monitoring information and toxicology testing can reveal safety issues such as overlapping controlled prescriptions or unexpected substance exposure. Interpret findings in clinical context and discuss unexpected results without punitive assumptions. Screening tests have detection limits and may not identify every opioid or explain when a substance was taken. The goal is safer care, including confirmation when needed, medication coordination, overdose prevention, and assessment for substance use disorder.
Apply it
A screening result does not show the prescribed opioid. Check the assay's capabilities, timing, and the patient's explanation before concluding diversion; use confirmatory testing when the result will materially affect a consequential clinical decision.
Common pitfall: A single unexpected test does not establish deception or justify dismissal from care. Monitoring should improve safety rather than replace clinical interpretation and patient discussion.
CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022
16.Which findings suggest local anesthetic systemic toxicity?
Local anesthetic systemic toxicity, or LAST, can cause circumoral symptoms, tinnitus, agitation, seizures, conduction disturbance, arrhythmia, and cardiovascular collapse. Sedation can obscure warning symptoms, and cardiovascular toxicity may occur without a classic neurological prodrome. Stop injection and activate emergency treatment when the clinical pattern suggests toxicity. Prevention combines appropriate dose selection, incremental injection, repeated aspiration, monitoring, and ultrasound when applicable; no single safeguard excludes intravascular injection or toxicity from systemic absorption.
Apply it
During a nerve block, tinnitus followed by a seizure and widening cardiac complexes should trigger the LAST response. A reassuring ultrasound image or earlier negative aspiration does not exclude the diagnosis.
Common pitfall: Do not wait for the complete classic sequence. Negative aspiration and ultrasound reduce some risks but do not eliminate systemic toxicity.
ASRA: Local Anesthetic Systemic Toxicity — A Problem-Based Learning Discussion
17.How does procedure risk determine an anticoagulant timing decision?
Assess the exact procedure, antithrombotic drug and dose, renal function, concurrent agents, and thrombotic indication. The 2018 second-edition interventional-pain guideline, summarized by ASRA in 2019, classifies dorsal root ganglion stimulation as high risk and thoracolumbar facet procedures as low risk. Its table recommends stopping apixaban three days before intermediate- or high-risk procedures and restarting after 24 hours; low-risk procedures require shared assessment rather than automatic application of that interval. Confined-space bleeding consequences and thrombosis from interruption must both inform planning.
Apply it
A patient taking apixaban 5 mg twice daily for nonvalvular atrial fibrillation, with creatinine clearance 85 mL/min, no previous stroke, and no concurrent antiplatelet therapy, is scheduled for elective permanent DRG stimulator implantation without an externalized trial lead. The prescriber agrees interruption is acceptable. Applying the 2018 second-edition guideline summarized in 2019, withhold apixaban for three full days before this high-risk procedure: for a Friday 08:00 implantation, the last dose is Tuesday 08:00. After uncomplicated implantation and secure hemostasis, resume Saturday 08:00, 24 hours afterward. New bleeding or neurological findings require reassessment before resumption.
Common pitfall: This worked interval does not automatically transfer to a low-risk thoracolumbar facet procedure, another anticoagulant, impaired clearance, or a trial with later lead removal. Lead removal creates another procedural bleeding event that must be included in the plan.
Updates to the ASRA Guidelines for Interventional Pain Procedures · PM_Content_Outline.pdf
18.How does LAST resuscitation differ from standard ACLS?
Stop local anesthetic delivery, call for help, and support oxygenation and ventilation because hypoxemia, hypercarbia, and acidosis worsen toxicity. Benzodiazepines are preferred for seizures. Use 20% lipid emulsion for serious LAST and modified circulatory resuscitation: smaller epinephrine doses are preferred, starting below 1 microgram/kg. Avoid additional local anesthetics, beta-blockers, calcium-channel blockers, and vasopressin. Use the ASRA LAST checklist for lipid administration, escalation, and observation.
Apply it
In cardiovascular collapse after a local anesthetic injection, provide ventilation and indicated chest compressions while initiating lipid rescue and the LAST-specific drug plan. Do not automatically import standard epinephrine dosing or vasopressin into this toxicological emergency.
Common pitfall: Propofol is not lipid-emulsion rescue, and large doses can worsen cardiovascular depression. Suppressing a seizure does not resolve the continuing risk of arrhythmia or collapse.
local-anesthetic-systemic-toxicity-rgb.pdf · ASRA: Local Anesthetic Systemic Toxicity — A Problem-Based Learning Discussion
19.How do diagnostic nerve blocks differ from lesioning?
A diagnostic local anesthetic block temporarily interrupts neural transmission to test whether a selected structure or pathway contributes to pain. Assess a predefined painful activity and the timing and magnitude of relief. Neurolysis or radiofrequency lesioning aims for a longer-lasting interruption by injuring the target pathway. Its selection therefore requires anatomical concordance, an appropriate indication, and discussion of sensory, motor, and other complications. A temporary response supports a hypothesis but does not guarantee durable benefit from lesioning.
Apply it
Before considering lesioning for localized pain, define the anatomical target and what a diagnostic block is intended to test. Record changes during the patient's usual provoking activity rather than relying only on comfort while resting after the procedure.
Common pitfall: Relief after an injection does not uniquely identify a pain generator if anesthetic spreads to adjacent structures. Diagnostic injection and destructive treatment have different purposes and risk profiles.
PM_Content_Outline.pdf · NCI: Cancer Pain (PDQ), Health Professional Version
20.What requires assessment when intrathecal analgesia changes unexpectedly?
Intrathecal drug delivery may help selected patients whose pain remains refractory or whose systemic analgesics cause intolerable adverse effects. Assess both drug toxicity and delivery-system complications. New sedation or slow breathing during intrathecal opioid treatment suggests opioid excess; abrupt loss of analgesia may reflect interrupted delivery and can be accompanied by withdrawal in a dependent patient. Fever, wound changes, or new neurological deficits require assessment for infection or another procedural complication. Reduced systemic exposure does not eliminate risk.
Apply it
A patient receiving intrathecal opioid therapy becomes unusually somnolent after a treatment adjustment. Assess ventilation and opioid toxicity promptly while reviewing the delivered drug, concentration, programming, and recent refill or dose changes.
Common pitfall: Do not respond to unexplained loss of analgesia solely by escalating the programmed dose. Investigate the patient and delivery system, and distinguish interruption from disease progression or tolerance.
PM_Content_Outline.pdf · NCI: Cancer Pain (PDQ), Health Professional Version
21.What must patients understand about epidural corticosteroid risk?
FDA labeling warns that epidural corticosteroid administration has been associated with rare but serious neurological events, including spinal cord infarction, paralysis, cortical blindness, stroke, and death. Corticosteroids are not FDA-approved for epidural administration, and safety and effectiveness for that route have not been established. Counseling should therefore address the proposed indication, alternatives, expected benefit, and serious risk rather than implying that common use or imaging guidance establishes regulatory approval.
Apply it
Before a proposed epidural steroid injection, explain the anticipated benefit and alternatives together with the FDA neurological warning and unapproved route. Document the discussion without suggesting that fluoroscopy eliminates the possibility of a serious complication.
Common pitfall: The warning is not evidence that every patient will be harmed or that every procedure is prohibited. It also cannot be dismissed because the technique is familiar.
22.How should spinal cord stimulation candidacy be assessed?
Establish a suitable pain indication, realistic goals, and the patient's understanding of device care. Use validated psychosocial screening, including depression assessment, and address important findings. The consensus recommends against offering stimulation with active psychosis or ongoing substance use disorder, including alcohol use disorder. Mild, remote, or treated substance use disorder requires individualized judgment rather than automatic exclusion. These qualifications and selection recommendations appear in the consensus guideline.
Apply it
A candidate has a positive depression screen and a remote treated substance use disorder. Evaluate current symptoms, stability, support, and expectations; neither a reassuring conversation nor the historical diagnosis alone completes the candidacy assessment.
Common pitfall: A positive depression screen is not automatically a permanent exclusion. Conversely, technically feasible implantation and previous medication failures do not override active psychosis or unresolved substance use concerns.
23.Why does methadone require drug-specific prescribing judgment?
Methadone combines mu-opioid receptor agonism with NMDA-receptor antagonism. Its long, variable elimination half-life creates accumulation risk, so initially acceptable analgesia does not exclude later respiratory depression during titration. Methadone can prolong the QT interval and has clinically important drug interactions. Conversion from another opioid is particularly complex because the equianalgesic relationship is variable. Assess interacting medicines and cardiac risk, and use experienced prescribing and close monitoring rather than a simple fixed conversion ratio.
Apply it
Before rotating a patient with cancer pain to methadone, review QT-prolonging medicines, relevant cardiac risk, and drug interactions. Avoid rapid escalation merely because the first doses have not yet produced the desired analgesia.
Common pitfall: NMDA antagonism does not remove methadone's opioid respiratory risk. Its pharmacology makes it unsuitable for casual substitution using an ordinary linear opioid conversion.
NCI: Cancer Pain (PDQ), Health Professional Version · CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022
24.What defines a successful spinal cord stimulation trial?
The consensus criterion for pain indications is at least 50% pain improvement measured with a validated instrument during or at the end of the trial, alongside functional assessment. In selected cases with less pain improvement, at least 50% functional improvement or more than 50% reduction in ongoing opioid use can support success case by case. Assess a realistic patient-specific activity or validated functional measure. A successful trial supports implantation consideration but cannot guarantee durable benefit.
Apply it
A patient reports 55% pain improvement and improved walking during a trial. Review tolerability and realistic expectations before implantation. For a patient reporting 40% pain improvement, substantial functional or opioid-use improvement warrants individualized review rather than an automatic success designation.
Common pitfall: Enthusiasm or a vague report of feeling better is insufficient to establish trial success. Apply the response criteria and functional assessment while recognizing the trial's predictive limitations.
25.How should exercise be prescribed for persistent pain?
Exercise is an active treatment that can improve function and pain in several chronic conditions. Select an approach suited to the diagnosis, current capacity, preferences, and practical circumstances, then progress it gradually. The goal is sustainable participation rather than a universally prescribed intensity. Distinguish expected exertional discomfort from new neurological deficits, acute injury, or other warning signs that warrant assessment. Activity goals should remain meaningful and measurable to the individual patient.
Apply it
A sedentary patient with persistent musculoskeletal pain wants to resume shopping independently. Begin a tolerable walking or strengthening plan linked to that goal, adjusting progression to response rather than requiring a demanding generic exercise target immediately.
Common pitfall: Advising exercise without specifying a feasible starting point can leave the patient unable to act. Conversely, routine discomfort does not automatically justify indefinite inactivity.
26.How does cognitive behavioral therapy support pain rehabilitation?
Cognitive behavioral therapy helps patients examine pain-related thoughts and behaviors and build coping strategies that support activity and function. It can address avoidance, distress, and unhelpful responses without requiring the conclusion that pain has a psychological origin. Pair it with condition-appropriate medical and physical care. Improvement may appear as greater participation or reduced interference even when pain intensity changes modestly, making functional assessment particularly important when evaluating its benefit.
Apply it
A patient avoids all bending because any discomfort is interpreted as fresh spinal damage. Combine pain education and cognitive behavioral strategies with a supported activity plan, helping the patient test safer beliefs and rebuild participation in valued tasks.
Common pitfall: Offering therapy as evidence that symptoms are imaginary undermines care. Psychological treatment can be useful alongside neurological, inflammatory, or degenerative disease and other indicated treatments.
27.When can mindfulness-based care contribute to pain treatment?
Mindfulness-based approaches can be considered among nonpharmacological options for selected chronic pain conditions. They train attention and responses to ongoing experience, potentially reducing distress and interference without requiring elimination of every painful sensation. Match the intervention to patient preference, condition-specific evidence, and access. It should complement an appropriate diagnostic and treatment plan rather than become a substitute for investigating new warning signs or treating a disease requiring specific medical care.
Apply it
A patient with stable chronic low back pain wants a nonmedication strategy for distress during symptom flares. Discuss a structured mindfulness-based option alongside exercise and functional goals, while preserving a plan for assessing genuinely new neurological symptoms.
Common pitfall: A broadly available wellness practice is not automatically an evidence-based treatment for every pain syndrome. Avoid promising that acceptance or attention training will remove an underlying lesion.
CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022 · CDC: Nonopioid Therapies for Pain Management
28.How should access barriers change a rehabilitation plan?
Cost, transportation, scheduling, language, and local availability can prevent participation in otherwise appropriate nonopioid care. Ask about these barriers before labeling treatment unsuccessful or the patient unwilling. Adapt the plan through feasible home activities, accessible services, or alternative delivery when clinically suitable. The therapeutic goal remains active rehabilitation; adapting delivery does not mean assuming that every substitute has identical evidence or that access problems make opioid escalation the default solution.
Apply it
A patient misses physical therapy because two bus transfers conflict with work. Develop a feasible home program and explore an accessible service rather than documenting failed rehabilitation or increasing medication simply because clinic attendance has been difficult.
Common pitfall: A referral is not equivalent to treatment received. Apparent nonadherence may reflect structural barriers, and an inaccessible plan cannot be fairly judged by its intended benefits.
29.Why combine treatments with different therapeutic targets?
Pain intensity, sleep disruption, emotional distress, and physical deconditioning can reinforce one another. A coordinated plan may combine medication, psychological treatment, and physical rehabilitation because each addresses different contributors to disability. Select components for the patient's condition, preferences, and goals rather than adding treatments indiscriminately. Compare benefits, harms, burdens, and feasible alternatives in understandable terms. Coordination clarifies who monitors adverse effects and progress; every component needs a defined purpose.
Apply it
A driver with neuropathic pain, poor sleep, and reduced walking confidence prioritizes alertness at work. Agree on symptom treatment and rehabilitation that account for sedation, track walking and work participation, and revisit choices as benefit, tolerability, access, or preferences change.
Common pitfall: Calling a plan multimodal does not establish that its components are effective or safe. Shared decisions require clinical guidance, and patient preference alone cannot establish efficacy or justify expected harms outweighing benefits.
CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022 · CDC: Nonopioid Therapies for Pain Management
30.How do malpractice elements and prescribing guidance differ?
The malpractice framework comprises duty, breach of duty, causation, and damages. An adverse outcome alone does not establish all four elements: the analysis must connect a departure from the applicable duty to actual harm. Also distinguish clinical guidelines from statutes, regulations, and institutional policies. The CDC opioid guideline explicitly provides voluntary clinical recommendations rather than universal legal dosage or duration limits. Controlled-substance and privacy requirements depend on the applicable legal setting.
Apply it
A patient develops sedation during opioid care. Identify the clinician's duty, whether assessment or monitoring fell below the applicable standard, whether that breach caused injury, and what damages occurred. A CDC dosage recommendation alone neither proves negligence nor supplies a jurisdiction's legal prescribing limit.
Common pitfall: Do not equate a complication with malpractice or treat a guideline threshold as legislation. Documentation should explain the indication, risk-benefit reasoning, counseling, monitoring, and response to new findings.
PM_Content_Outline.pdf · CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022
Clinical States50%
31.What distinguishes nociplastic pain from other mechanisms?
Nociplastic pain arises from altered nociception despite no clear evidence of actual or threatened tissue damage activating peripheral nociceptors or disease or lesion of the somatosensory system causing the pain. These exclusions distinguish the mechanism from nociceptive and neuropathic pain. Mixed mechanisms can coexist, so classification must explain the clinical presentation rather than force every symptom into one category. Normal imaging alone is insufficient to establish a nociplastic mechanism.
Apply it
A patient has persistent widespread hypersensitivity without sufficient tissue injury or an explanatory somatosensory lesion. Consider a nociplastic contribution after clinical assessment, while recognizing that a separate arthritic joint can still generate concurrent nociceptive pain.
Common pitfall: Unexplained pain is not automatically nociplastic. The definition includes both the tissue-damage and somatosensory-lesion exclusions, and it does not imply an imagined experience.
32.How do the 2016 revised criteria distinguish fibromyalgia from regional pain?
The 2016 revised criteria require WPI ≥7 with SSS ≥5, or WPI 4–6 with SSS ≥9; pain in at least four of five regions; and symptoms generally present for at least three months. Regions are left upper, right upper, left lower, right lower, and axial. Jaw, chest, and abdominal pain count toward WPI but not the generalized-region requirement. WPI counts painful sites during the preceding week, from 0–19. SSS adds past-week severity ratings of 0–3 each for fatigue, unrefreshing sleep, and cognitive symptoms, plus one point each for headaches, lower abdominal pain/cramps, and depression during the preceding six months. See the [2016 criteria paper](https://www.fai2r.org/wp-content/uploads/2018/11/Anx_tuto_fibromyalgie_FAI2R-wolfe2016.pdf).
Apply it
After six months of symptoms, pain in both shoulder girdles, both upper arms, both hips, and the lower back gives WPI 7 across all five regions. With SSS 6, this qualifies. Conversely, WPI 7 and SSS 10 confined to both upper regions and the axial region fails the distribution requirement. Care emphasizes education, gradually increased exercise, sleep management, and individualized psychological or medication support.
Common pitfall: Normal inflammatory tests do not establish fibromyalgia. Coexisting diseases do not invalidate qualifying fibromyalgia, and fibromyalgia does not exclude other important illnesses. New swollen joints or focal weakness require assessment rather than automatic attribution to fibromyalgia.
33.How is acute compartment syndrome recognized and treated?
Rising pressure in a closed muscle compartment compromises tissue perfusion and threatens irreversible muscle and nerve injury. Important early clues include disproportionate pain, pain with passive muscle stretch, and a tense compartment. Sensory changes may occur; paralysis and absent pulses are late findings. Acute compartment syndrome requires emergency surgical assessment and fasciotomy when diagnosed. Pressure measurement can assist an uncertain diagnosis or unreliable examination but should not delay specialist assessment. Analgesia alone leaves the pressure-driven threat untreated.
Apply it
After a tibial fracture, escalating pain despite analgesia, a tense calf, and severe passive toe-movement pain require emergency surgical assessment despite a warm foot and palpable pedal pulse. Address external constriction while the team assesses the need for decompression.
Common pitfall: A preserved pulse or temporary analgesic response does not establish adequate compartment perfusion. Waiting for pulselessness, paralysis, or routine outpatient review risks advanced injury.
34.What findings meet the Budapest clinical criteria for CRPS?
The [Budapest clinical criteria](https://pmc.ncbi.nlm.nih.gov/articles/PMC2914601/) require continuing pain disproportionate to the inciting event, at least one reported symptom in three of four categories, and at least one observed sign in two or more categories at evaluation, with no better explanation. Categories are sensory, vasomotor, sudomotor/edema, and motor/trophic. Examples include allodynia or pinprick hyperalgesia; temperature or color asymmetry; edema or sweating asymmetry; and reduced movement, motor dysfunction, or hair, nail, and skin changes.
Apply it
Weeks after a wrist fracture, a patient reports touch pain, color changes, swelling, and stiffness. Examination shows allodynia, temperature asymmetry, edema, and reduced movement. The symptom and sign thresholds are met; exclude infection, vascular compromise, and another better explanation before diagnosing CRPS.
Common pitfall: Severe regional pain or a history of swelling alone is insufficient. Reported symptoms and currently observed signs have different thresholds; do not substitute the stricter research symptom rule for the clinical rule.
35.How should common acute musculoskeletal pain be treated?
For many common acute musculoskeletal conditions, nonopioid therapies are at least as effective as opioids. Match treatment to the injury using appropriate supportive measures and nonopioid medication after reviewing contraindications. First assess for injuries requiring specific management. If severe acute pain justifies an opioid, prescribe no greater quantity than needed for the expected severe phase, explain as-needed use, and reassess an unexpected recovery course. Duration depends on the condition and patient rather than a universal fixed course.
Apply it
An adult has a minor ankle sprain without fracture or neurovascular compromise. Discuss suitable supportive measures and nonopioid analgesia. If an injury warrants a short opioid course, match the supply to anticipated severe pain and reassess persistent or worsening symptoms rather than automatically extending it.
Common pitfall: Acute pain alone does not establish an opioid indication. Avoid both excessive default supplies and rigid duration limits that ignore the injury or clinical course.
CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022
36.How should pain be assessed in children who differ in communication ability?
Choose assessment by developmental and communication ability. A child able to use a faces scale supplies their own rating; the clinician or parent should not select the face for them. For young or nonverbal children, structured behavioral assessment can supplement examination and caregiver observations. FLACC scores face, legs, activity, cry, and consolability; revised FLACC accommodates children with developmental or cognitive impairment. The [Royal Children's Hospital guideline](https://www.rch.org.au/clinicalguide/guideline_index/Acute_pain_management/) emphasizes regular reassessment, function, physiology, and response to treatment.
Apply it
A nonverbal child with developmental disability becomes less mobile and difficult to console after surgery. Use revised FLACC with caregiver descriptions of usual behavior, inspect for complications, provide appropriate analgesia, and reassess after its expected onset. For a communicative school-age child, obtain self-report directly.
Common pitfall: Quiet behavior does not exclude pain, and tachycardia or distress alone does not identify its cause. Adult outpatient opioid recommendations cannot be applied automatically to pediatric care.
PM_Content_Outline.pdf · IASP Terminology · CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022
37.When is a topical NSAID appropriate for knee osteoarthritis?
The 2026 ACR summary strongly recommends topical NSAIDs for knee osteoarthritis and strongly recommends oral NSAIDs for knee, hip, and hand osteoarthritis. It conditionally recommends topical over oral NSAIDs for knee and hand disease. These are different recommendation strengths addressing different comparisons. For an accessible joint such as the knee, topical treatment can provide local therapy with less systemic exposure, while individual risks and preferences still shape selection.
Apply it
A patient has localized knee osteoarthritis and wishes to limit systemic medication exposure. Discuss a topical NSAID as a strongly supported treatment, explaining that the preference over oral NSAIDs is conditional and still requires assessment of individual circumstances.
Common pitfall: Do not turn a conditional topical-over-oral recommendation into an absolute rule. Also avoid using the older guideline's hand recommendation strength when describing the 2026 summary.
38.Why does joint depth matter for topical osteoarthritis treatment?
The hip lies deeper beneath the skin than the knee or hand joints, limiting the expected delivery and benefit of a topical NSAID at the hip. The older ACR guideline explains this anatomical rationale, while the 2026 summary provides current recommendation strengths for topical and oral NSAIDs. Treatment evidence should therefore remain joint-specific. A topical drug that is useful at the knee cannot simply be assumed equally effective for hip joint pain.
Apply it
A patient with radiographically supported hip osteoarthritis wants the same topical NSAID that helped a relative's knee. Explain the depth limitation and review suitable alternatives, accounting for oral medication risks and the patient's broader functional treatment plan.
Common pitfall: Do not extrapolate a superficial-joint recommendation to the hip. Equally, deep hip pain still needs diagnostic assessment rather than being assigned to osteoarthritis solely from location.
2019 ACR/Arthritis Foundation Guideline for Management of Osteoarthritis of the Hand, Hip, and Knee · 2026 Update of the American College of Rheumatology Recommendations for the Management of Osteoarthritis of the Knee, Hip, and Hand
39.How do exercise and weight management support osteoarthritis care?
Exercise supports strength, mobility, and function in osteoarthritis rather than merely distracting from joint pain. Weight management can add benefit for appropriate patients with overweight or obesity, particularly when weight-bearing joints are affected. Choose an achievable program and connect it to daily activities. Medication can facilitate participation, but it does not replace the functional role of movement. Progress should be judged by capability and tolerability as well as pain intensity.
Apply it
A patient with knee osteoarthritis and obesity struggles with stairs. Agree on a feasible strengthening and activity plan, discuss weight-management support, and use suitable symptom treatment to enable participation rather than waiting for pain to disappear before movement begins.
Common pitfall: Telling patients simply to lose weight provides little actionable help. Avoid making all pain care conditional on weight loss or prescribing exercise beyond current capacity.
CDC: Nonopioid Therapies for Pain Management · 2019 ACR/Arthritis Foundation Guideline for Management of Osteoarthritis of the Hand, Hip, and Knee
40.Which clinical and imaging findings support lumbar spinal stenosis?
Lumbar spinal stenosis narrows space for neural structures and can produce leg pain, numbness, or weakness during standing or walking. Sitting or forward flexion often helps by increasing available space, supporting neurogenic claudication. Examine neurological and vascular findings and correlate anatomical narrowing with symptoms. MRI characterizes neural and soft-tissue structures; other imaging may clarify bone. Degeneration or narrowing alone does not establish the symptomatic pain generator.
Apply it
An older adult has bilateral leg symptoms while standing or walking upright that ease when seated or leaning over a cart. Correlate this pattern with examination and imaging. If symptoms are unrelated to posture or suggest vascular disease, investigate the discrepancy before selecting a spinal intervention.
Common pitfall: Anatomical severity and symptom burden may differ. Progressive weakness or new bladder or saddle symptoms changes urgency and cannot be treated as an incidental degenerative finding.
AAOS OrthoInfo: Lumbar Spinal Stenosis · AANS: Cauda Equina Syndrome
41.How do trigeminal neuralgia and temporomandibular pain differ?
ICHD-3 trigeminal neuralgia features severe unilateral electric or stabbing paroxysms lasting a fraction of a second to two minutes, triggered by innocuous stimuli within a trigeminal distribution. Temporomandibular disorder instead has a painful jaw or masticatory process; headache attribution requires at least two causal features: temporal association, aggravation by jaw function, or examination provocation. Sensory loss warrants investigation for a secondary neuralgia cause.
Apply it
Seconds-long cheek shocks triggered by light touch suggest trigeminal neuralgia. Temporal aching that began with a painful jaw disorder, worsens with chewing, and is reproduced by temporalis palpation supports TMD-related headache.
Common pitfall: Chewing can trigger both disorders. Use attack duration, quality, examination, and anatomical distribution. Vascular contact alone does not establish classical trigeminal neuralgia; compression with nerve morphological change is required.
The International Classification of Headache Disorders, 3rd edition
42.When does back pain suggest cauda equina syndrome?
Cauda equina syndrome results from dysfunction of the lumbosacral nerve roots and can produce urinary retention or other bladder dysfunction, saddle sensory loss, bowel dysfunction, and leg neurological deficits. These features require emergency evaluation for a compressive cause. New difficulty emptying the bladder is especially important and should not be dismissed because pain is longstanding. Prompt assessment and appropriate imaging are needed rather than routine outpatient treatment for presumed uncomplicated sciatica.
Apply it
A patient with back and leg pain develops reduced perineal sensation and cannot empty the bladder normally. Arrange emergency evaluation for cauda equina compression instead of prescribing another analgesic and scheduling a standard follow-up visit.
Common pitfall: Waiting for complete incontinence or profound paralysis can delay recognition. A history of chronic back pain does not make new bladder or saddle symptoms benign.
43.When can duloxetine be considered for osteoarthritis pain?
Duloxetine is a nonopioid option with evidence for osteoarthritis pain and can be considered when appropriate, including when NSAID treatment is unsuitable or insufficient. Its role reflects modulation of pain processing rather than correction of cartilage loss. Review comorbidities, interactions, tolerability, and patient preferences before use. Coexisting depression may influence selection, but analgesic consideration does not require assuming that the joint pain is caused by depression or lacks a structural basis.
Apply it
A patient with symptomatic osteoarthritis has persistent pain despite rehabilitation and cannot tolerate oral NSAIDs. Discuss duloxetine among suitable alternatives, comparing expected symptom benefit and adverse effects while maintaining exercise and functional goals as central parts of treatment.
Common pitfall: Choosing duloxetine does not establish a psychiatric cause of pain. It also does not restore joint anatomy or remove the need to assess new mechanical symptoms.
CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022
44.Why must cancer pain be distinguished from the CDC prescribing scope?
The CDC outpatient opioid guideline excludes cancer-related pain treatment, sickle cell disease pain, palliative care, and end-of-life care. Cancer pain requires its own disease-informed assessment and individualized analgesic plan, often including opioids when indicated. Exclusion does not remove the need for safety monitoring; it means recommendations must come from appropriate cancer-care evidence. Consider pain mechanism, cancer treatment, organ function, prior opioid exposure, and the patient's goals when planning treatment.
Apply it
A patient with painful metastatic disease needs analgesic adjustment. Use cancer-pain guidance and the clinical context rather than applying an outpatient noncancer opioid recommendation as a mandatory ceiling or reason to withhold appropriately indicated treatment.
Common pitfall: Guideline exclusion does not mean unrestricted prescribing. It means that a different evidence base and clinical framework should guide decisions, with continued attention to adverse effects.
CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022 · NCI: Cancer Pain (PDQ), Health Professional Version
45.Why should constipation prevention accompany cancer opioid treatment?
Opioids reduce gastrointestinal motility and commonly cause constipation, with tolerance to this effect often limited. Preventive bowel management should therefore accompany ongoing opioid treatment when appropriate rather than waiting for substantial discomfort or impaction. Assess baseline bowel habits, hydration, other constipating medicines, and possible obstruction. A stimulant-based regimen is commonly used, with additional measures individualized. New abdominal symptoms still require evaluation rather than automatic attribution to an expected medication effect.
Apply it
A patient beginning regular opioid therapy for cancer pain has normal bowel movements and no evidence of obstruction. Discuss prevention and start an appropriate bowel regimen now rather than waiting until several days without stool produce distress and treatment difficulty.
Common pitfall: A stool softener alone may be insufficient for opioid-related motility reduction. Conversely, suspected bowel obstruction requires assessment rather than reflexively increasing laxatives without considering the cause.
46.How should breakthrough cancer pain be characterized?
Breakthrough pain is a transient exacerbation occurring against a background pain state that is otherwise relatively controlled. Characterize onset, duration, triggers, frequency, and response to rescue treatment. Predictable movement-related episodes differ from pain returning before each scheduled dose, which may indicate inadequate background coverage. Frequent episodes should prompt reassessment of the disease and baseline plan. Rescue selection must consider opioid tolerance and product-specific restrictions rather than using all rapid-onset formulations interchangeably.
Apply it
A patient has good comfort at rest but brief severe pain during transfers. Identify the movement trigger and review a tailored episode-management plan, while distinguishing this pattern from recurrent pain before every scheduled background dose.
Common pitfall: Calling all uncontrolled cancer pain breakthrough pain can obscure inadequate baseline treatment. Rapid-onset opioid products also have specific eligibility and safety requirements that cannot be assumed interchangeable.
47.How can cancer produce mixed pain mechanisms?
Cancer-related pain may arise from tissue injury, nerve involvement, treatment effects, or several mechanisms together. A patient can therefore have localized aching from skeletal disease alongside burning or electric pain from nerve injury. Identifying the components helps guide disease-directed treatment, analgesics, and appropriate adjuvants. Do not assume every new symptom is an expected extension of known cancer pain; changes in distribution or neurological function can signal a complication requiring specific evaluation.
Apply it
A patient with cancer has deep pelvic aching and new shooting pain with focal sensory change. Evaluate for nerve involvement and a changing disease process while considering a mixed analgesic strategy rather than escalating a single drug without reassessment.
Common pitfall: The label cancer pain does not identify one mechanism or treatment. New neurological deficits should trigger investigation rather than being managed only as a higher pain score.
48.How are pancreatic symptoms and tests matched to the clinical question?
Pancreatitis commonly causes upper abdominal pain that may radiate to the back. Acute inflammation can be assessed with serum lipase or amylase in the clinical context. CT, MRCP, and endoscopic ultrasound address pancreatic structure or ductal disease; abdominal ultrasound can identify gallstones. In chronic disease, weight loss and greasy stools suggest impaired digestion, for which stool fat testing addresses malabsorption. Secretin-stimulated pancreatic function testing evaluates pancreatic secretory response and is available at selected centers.
Apply it
A patient with recurrent pancreatic pain develops weight loss and oily stools. Assess malabsorption and structural disease rather than repeatedly ordering only serum lipase. New severe pain or vomiting also warrants assessment for acute inflammation and other urgent abdominal causes.
Common pitfall: Pancreatic pain, acute inflammation, structural disease, and exocrine insufficiency are distinct clinical questions. A normal acute enzyme result does not establish normal digestion or exclude chronic structural disease.
49.How does visceral cancer pain guide plexus-block selection?
The anatomical distribution and mechanism of cancer pain guide interventional selection. Celiac plexus intervention is used particularly for upper abdominal visceral pain from pancreatic cancer. Superior hypogastric plexus and ganglion impar interventions address selected lower abdominal or pelvic pain patterns. These targets are not interchangeable, and mixed somatic or neuropathic pain may require additional treatment. Consider a targeted intervention when regional pain remains difficult to control or systemic treatment produces unacceptable adverse effects.
Apply it
A patient with pelvic malignancy has refractory deep pelvic pain and substantial opioid adverse effects. Characterize visceral, somatic, and neuropathic components before selecting a pelvic neural target; an intervention used for pancreatic upper abdominal pain is not automatically appropriate.
Common pitfall: Organ location alone does not establish a block indication. Confirm that the proposed pathway plausibly carries the pain being treated, and reassess new pain for disease progression or another complication.
NCI: Cancer Pain (PDQ), Health Professional Version · PM_Content_Outline.pdf
50.When do headache and medication use meet medication-overuse criteria?
ICHD-3 medication-overuse headache requires headache on at least 15 days per month in a person with a pre-existing headache disorder and regular overuse of acute headache medication for more than three months. The medication threshold depends on class: triptans, opioids, and combination analgesics generally use at least 10 days monthly; nonopioid analgesics generally use at least 15. Count use days rather than tablets, and assess mixed-class patterns separately.
Apply it
A patient with migraine has headache on twenty days monthly and takes a triptan on twelve days monthly for four months. The frequency, pre-existing disorder, duration, and triptan-use threshold support medication-overuse headache alongside the underlying headache diagnosis.
Common pitfall: Do not apply the nonopioid-analgesic threshold to triptans. Medication use alone is insufficient without the required headache frequency, duration, and underlying headache context.
The International Classification of Headache Disorders, 3rd edition
51.Which features distinguish common primary headache syndromes?
Migraine without aura typically combines attacks lasting 4–72 hours with features such as pulsating pain, activity aggravation, nausea, or paired light and sound sensitivity. Tension-type headache more often has pressing bilateral pain without routine activity aggravation. Cluster headache features severe unilateral orbital, supraorbital, or temporal attacks lasting 15–180 minutes with ipsilateral autonomic signs or restlessness. These patterns guide classification but do not eliminate the need to assess secondary-headache warning features.
Apply it
A patient has repeated hour-long unilateral orbital attacks with tearing and pacing, rather than lying still. The duration, autonomic findings, and restlessness support a cluster pattern more strongly than a generic description of severe headache would.
Common pitfall: Pain severity alone does not distinguish migraine from cluster headache. Use attack duration, behavior, accompanying symptoms, and the full diagnostic criteria rather than one striking feature.
International Headache Society: International Classification of Headache Disorders · The International Classification of Headache Disorders, 3rd edition
52.When is persistent zoster pain postherpetic neuralgia, and who is at greater risk?
The CDC defines postherpetic neuralgia as pain continuing in the prior herpes zoster rash area for more than 90 days after rash onset. Measure from onset rather than skin healing. Older age, greater acute pain, and more severe rash increase risk, but do not make persistent pain inevitable. Nerve-related pain may continue after lesions resolve and substantially disrupt sleep and function.
Apply it
An older adult had a severe thoracic rash beginning four months ago and now has burning pain and clothing sensitivity in that distribution. The location and onset-based interval support postherpetic neuralgia. Explain why healed skin does not ensure nerve-pain resolution and assess daily interference.
Common pitfall: Starting the clock at healing changes the definition. A risk factor is not a diagnosis, and pain in a new distribution requires assessment rather than automatic attribution to prior zoster.
53.How do allodynia and hyperalgesia differ?
Allodynia is pain from a stimulus that does not normally provoke pain, such as light brushing. Hyperalgesia is increased pain from a stimulus that normally provokes pain, such as a pinprick. The distinction concerns the stimulus-response relationship, not simply how severe the pain feels. Both findings describe altered sensitivity and can occur in different clinical mechanisms, so they should be documented precisely without being treated as a complete diagnosis.
Apply it
During examination, gentle cotton contact hurts and a pinprick feels unusually painful. Document allodynia for the cotton response and hyperalgesia for the exaggerated pinprick response, then interpret the distribution alongside the suspected disease and other neurological findings.
Common pitfall: Calling every exaggerated response allodynia loses the distinction between normally nonpainful and painful stimuli. Neither term alone proves neuropathic pain or identifies a specific lesion.
54.How do radicular pain and neurological deficit differ?
Nerve-root irritation or compression can produce radiating limb pain, while impaired root function can also produce weakness, sensory loss, or reflex change. These findings are related but not interchangeable: pain severity does not measure the degree of neurological dysfunction. Examine function explicitly and compare symptoms with the expected anatomical distribution. Progressive weakness or new sphincter and saddle symptoms changes the urgency of assessment even when the patient has familiar longstanding radiating pain.
Apply it
A patient with recurrent leg pain now has difficulty lifting the foot. Document and assess the new motor deficit rather than treating this as an ordinary pain flare because the reported pain intensity is similar to previous episodes.
Common pitfall: A dramatic pain score does not establish motor impairment, and modest pain does not exclude important weakness. New neurological findings require their own assessment and response.
AAOS OrthoInfo: Lumbar Spinal Stenosis · AANS: Cauda Equina Syndrome
55.Which pattern supports painful diabetic polyneuropathy?
Painful diabetic polyneuropathy commonly produces distal, often symmetrical sensory symptoms in the feet with compatible sensory abnormalities. Diabetes makes the diagnosis plausible but does not explain every painful or numb limb automatically. Marked asymmetry, abrupt onset, or a focal neurological pattern should prompt consideration of another process. Once the condition is established, assess pain, mood, sleep, and functional effects so treatment targets the patient's actual burden rather than the diagnostic label alone.
Apply it
A patient with diabetes describes slowly progressive burning in both feet and distal sensory loss. Consider painful polyneuropathy, but investigate a separate abrupt unilateral foot weakness rather than attributing every new neurological symptom to the established diabetic condition.
Common pitfall: Diabetes is a risk factor, not a universal explanation. Atypical distribution or time course should reopen diagnostic reasoning before another neuropathic pain medication is simply added.
AAN: Oral and Topical Treatment of Painful Diabetic Polyneuropathy
56.What supports central neuropathic pain after stroke?
Central neuropathic pain requires a lesion or disease of central somatosensory pathways. Match pain and sensory abnormalities to lesion anatomy. For facial or head pain, ICHD-3 central post-stroke pain requires onset within six months of stroke, an appropriately located vascular lesion on imaging, and no better explanation. Limb or trunk symptoms may coexist.
Apply it
Two months after a thalamic stroke, burning facial and limb pain develops in the anatomically concordant sensory territory with impaired temperature sensation and allodynia. These findings support central neuropathic pain; painful restricted shoulder movement may have a separate musculoskeletal cause.
Common pitfall: Central neuropathic pain differs from nociplastic pain because an explanatory central somatosensory lesion exists. A stroke history alone cannot explain pain at an anatomically discordant site.
IASP Terminology · The International Classification of Headache Disorders, 3rd edition
57.Why should sickle cell pain treatment begin promptly?
Vaso-occlusive pain is primarily a clinical diagnosis, and laboratory results do not reliably validate or quantify an individual's pain episode. Begin prompt individualized analgesia while evaluating for complications and other causes of symptoms. Prior effective regimens and an established care plan can guide treatment. The absence of dramatic laboratory abnormalities does not justify withholding relief, and a known pain history does not eliminate the need to assess fever, respiratory symptoms, or other warning findings.
Apply it
A patient with sickle cell disease reports pain typical of previous vaso-occlusive episodes, with stable initial vital signs and routine laboratory values. Start the individualized analgesic plan promptly while continuing assessment rather than waiting for a laboratory marker to confirm the pain.
Common pitfall: Neither normal laboratory results nor a calm appearance excludes severe pain. Conversely, familiarity with prior episodes must not obscure a new complication requiring additional treatment.
ASH: Emergency Department Management of Sickle Cell Disease — A Point-of-Care Tool
58.How does older age change pain medication assessment?
Older adults may have increased vulnerability to sedation, falls, drug interactions, and accumulation related to impaired renal or hepatic function. Assessment should include cognition, medication management, comorbidity, and available support rather than age alone. Select treatment and monitoring accordingly, with particular attention to combinations of central nervous system depressants. Pain remains important to treat, but an apparently familiar dose can have a different risk profile in a patient whose physiological reserve has changed.
Apply it
An older patient becomes unsteady after a sedating pain medicine is added to several other prescriptions. Review renal function, interacting drugs, cognition, and falls risk before treating the symptom only with a walking aid or assuming it reflects aging.
Common pitfall: Chronological age does not mandate undertreatment or one universal dose. Functional status, organ function, interactions, and observed response provide the clinically useful basis for individualization.
CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022 · FDA: Gabapentin and pregabalin — serious breathing problems
59.How should pregnancy affect opioid decisions?
Pregnancy requires balancing maternal pain treatment with maternal and fetal risks, rather than assuming pain must remain untreated. Discuss risks and benefits, emphasize appropriate alternatives, and use individualized care when an opioid is necessary. For a pregnant patient already receiving opioids, seek appropriate expertise before tapering because withdrawal can pose risks. Opioid use disorder requires evidence-based treatment and coordinated obstetric care, a different decision from simply changing an analgesic prescription.
Apply it
A pregnant patient taking long-term opioids asks whether to stop immediately. Review the indication and dependence, coordinate appropriate obstetric and pain expertise, and plan any change carefully rather than advising abrupt cessation solely because pregnancy has been identified.
Common pitfall: Pregnancy is neither an automatic reason to deny analgesia nor a reason to continue every regimen unchanged. Abrupt self-directed withdrawal can create avoidable maternal and fetal risks.
CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022
60.How should pain care continue when opioid use disorder is present?
Opioid use disorder and pain can coexist, requiring treatment of both. Offer or arrange evidence-based medication treatment for the disorder and continue appropriate pain management, including nonopioid and nonpharmacological measures. Buprenorphine or methadone treatment can be relevant to both the addiction-care context and pain planning, but implementation depends on the clinical situation. Detoxification alone is not adequate treatment for opioid use disorder, and dismissal from care increases risk rather than resolving the problem.
Apply it
A patient with chronic pain meets diagnostic criteria for opioid use disorder. Discuss medication treatment and overdose prevention while developing a continuing pain plan, rather than ending care or requiring untreated withdrawal before any further clinical support is provided.
Common pitfall: Physical dependence alone does not establish opioid use disorder. Once the disorder is identified, simply tapering analgesics without offering effective treatment leaves a major clinical need unaddressed.
CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022
What to focus on during revision
The following are CertMedbry study suggestions. Use the official outline to check the full scope of your examination.
- Divide study time approximately equally between General and Clinical States, then emphasize pharmacotherapy, procedures, and musculoskeletal pain within those domains.
- Distinguish pain descriptors from demonstrated mechanisms: nociceptive, neuropathic, and nociplastic classifications require different supporting evidence.
- Recognize time-critical patterns: compartment syndrome, cauda equina dysfunction, local anesthetic toxicity, respiratory depression, and sickle cell complications.
- Practise medication decisions using named agents, mechanisms, organ function, interactions, functional benefit, guideline population, and patient preferences.
- Apply procedure-risk classification and drug-specific interruption and resumption timing; distinguish diagnostic blocks, lesioning, intrathecal complications, and stimulation trial outcomes.
- Use exact diagnostic distinctions for CRPS, central neuropathic pain, orofacial pain, headache overuse, and persistent zoster pain.
- Match pediatric pain assessment to communication ability and distinguish clinical guidance from legal prescribing requirements.
- Extend study beyond this selective guide using every subdivision of the official blueprint and its full content outline.
A practical preparation plan
1. Map the official scope
Create a study map from the official General and Clinical States subdivisions. Allocate half your study time to each major domain and identify anatomical, procedural, regulatory, and special-population topics requiring study beyond these 60 concepts.
2. Build discriminating comparisons
Compare allodynia with hyperalgesia, central neuropathic with nociplastic pain, trigeminal neuralgia with temporomandibular pain, CRPS symptoms with observed signs, and physical dependence with opioid use disorder.
3. Rehearse urgent decisions
For each emergency pattern, state the decisive clinical findings, immediate action, and tempting delay to avoid. Include preserved pulses in compartment syndrome, new bladder dysfunction during back pain, and drug modifications during LAST resuscitation.
4. Practise treatment selection
Work through medication and procedural cases by naming the indication, mechanism, expected functional benefit, major patient-specific risk, monitoring interval, and reason to reconsider treatment. Specify the procedure, anticoagulant regimen, renal function, thrombotic indication, and guideline version before selecting interruption and resumption timing.
5. Use the drills diagnostically
Complete the 20 questions before reading explanations. Record whether each error arose from a missed cue, mechanism confusion, arithmetic, recommendation strength, or guideline-scope mistake; then use the flashcards to recall the corrected principle.
6. Expand and revisit
Return to the full official scope after reviewing weak areas. Add broader specialty reading and clinical cases, then revisit functional outcomes, procedural safety, headache thresholds, special populations, and high-risk medication combinations using spaced recall.
Use your sample score as a starting point
The free set contains 20 original practice questions. It is a small learning sample, not an official examination or a validated pass prediction. Review each explanation and its source before moving to another topic.
Start the free sampleOfficial sources and updates
- ABFM: Pain Medicine
- ABFM: Pain Medicine One-Day Exam
- 2026 Pain Medicine CAQ One-Day Examination Information Booklet
- ABA: Pain Medicine Exam
- Pain Medicine Exam Blueprint
- Cochrane Handbook, Chapter 15: Interpreting results and drawing conclusions
- CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022
- FDA: Gabapentin and pregabalin — serious breathing problems
- AAN: Oral and Topical Treatment of Painful Diabetic Polyneuropathy
- AAN Issues Guideline for Treatment of Painful Diabetic Neuropathy
- ASRA: Local Anesthetic Systemic Toxicity — A Problem-Based Learning Discussion
- FDA prescribing information: Kenalog-10 Injection
- Evidence-based consensus guidelines on patient selection and trial stimulation for spinal cord stimulation therapy for chronic non-cancer pain
- CDC: Nonopioid Therapies for Pain Management
- IASP Terminology
- AAOS OrthoInfo: Compartment Syndrome
- AANS: Cauda Equina Syndrome
- 2019 ACR/Arthritis Foundation Guideline for Management of Osteoarthritis of the Hand, Hip, and Knee
- AAOS OrthoInfo: Lumbar Spinal Stenosis
- American College of Rheumatology: Fibromyalgia
- NCI: Cancer Pain (PDQ), Health Professional Version
- NIDDK: Pancreatitis
- NIDDK: Diagnosis of Pancreatitis
- International Headache Society: International Classification of Headache Disorders
- The International Classification of Headache Disorders, 3rd edition
- CDC: Clinical Features of Shingles
- ASH: Emergency Department Management of Sickle Cell Disease — A Point-of-Care Tool
- ACR: Osteoarthritis Clinical Practice Guidelines
- 2026 Update of the American College of Rheumatology Recommendations for the Management of Osteoarthritis of the Knee, Hip, and Hand
- PM_Content_Outline.pdf
- Checklist for Treatment of Local Anesthetic Systemic Toxicity (LAST)
- local-anesthetic-systemic-toxicity-rgb.pdf
- Updates to the ASRA Guidelines for Interventional Pain Procedures
- How I Do It: Weaning Strategy for Intrathecal Drug Delivery Systems for Chronic Non-Cancer Pain: Sublingual Buprenorphine-Naloxone Microdosing Schedule
- 2026-Examination-Information-Booklet-Pain-Medicine-v.1.0.pdf
- DailyMed - DULOXETINE DELAYED-RELEASE- duloxetine hydrochloride capsule, delayed release pellets
- DailyMed - PREGABALIN capsule
- DailyMed - OXCARBAZEPINE tablet, film coated
- DailyMed - AMITRIPTYLINE HCL tablet, film coated
- Validation of proposed diagnostic criteria (the “Budapest Criteria”) for Complex Regional Pain Syndrome - PMC
- Anx_tuto_fibromyalgie_FAI2R-wolfe2016.pdf
- Clinical Practice Guidelines : Acute pain management
- Symptoms & Causes of Pancreatitis - NIDDK
Confirm current eligibility, fees, scheduling and policies directly with the examination provider. CertMedbry is independent and is not endorsed by these organisations. How we handle content and corrections.